NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70518-1881-00 | 70518-1881 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Feb. 19, 2019 | March 8, 2019 | No Longer Used | |
42747-0327-07 | 42747-0327 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | Oct. 27, 2016 | In Use | |
42747-0327-30 | 42747-0327 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | In Use | ||
42747-0327-72 | 42747-0327 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | In Use | ||
43353-0687-60 | 43353-0687 | conjugated estrogens | Premarin | 0.3 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 1, 2006 | In Use | ||
43353-0688-60 | 43353-0688 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 1, 2006 | In Use | ||
49999-0109-00 | 49999-0109 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | March 21, 2012 | Jan. 1, 2013 | In Use | |
49999-0109-30 | 49999-0109 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | March 21, 2012 | Jan. 1, 2013 | In Use | |
49999-0109-90 | 49999-0109 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | March 21, 2012 | June 1, 2012 | In Use | |
53808-0770-01 | 53808-0770 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | July 1, 2009 | In Use | ||
54868-0451-00 | 54868-0451 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 8, 2005 | May 12, 2014 | In Use | |
54868-0451-02 | 54868-0451 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 8, 2005 | In Use | ||
54868-0451-06 | 54868-0451 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 8, 2005 | In Use | ||
69189-1105-01 | 69189-1105 | Estrogens, Conjugated | Premarin | 0.9 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2015 | May 24, 2017 | No Longer Used | |
52544-0092-76 | 52544-0092 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | March 11, 2010 | Oct. 31, 2018 | No Longer Used | |||
52544-0153-02 | 52544-0153 | Triptorelin Pamoate | Trelstar | 3.75 mg/2mL | Hormonal Therapy | GnRH Agonist | Intramuscular | June 15, 2000 | Oct. 31, 2018 | No Longer Used | |
52544-0154-02 | 52544-0154 | Triptorelin Pamoate | Trelstar | 11.25 mg/2mL | Hormonal Therapy | GnRH Agonist | Intramuscular | June 29, 2001 | Oct. 31, 2018 | No Longer Used | |
52544-0156-02 | 52544-0156 | Triptorelin Pamoate | Trelstar | 22.5 mg/2mL | Hormonal Therapy | GnRH Agonist | Intramuscular | March 11, 2010 | Oct. 31, 2018 | No Longer Used | |
52544-0188-76 | 52544-0188 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | June 29, 2001 | Oct. 31, 2018 | No Longer Used | |||
52544-0189-76 | 52544-0189 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | June 15, 2000 | Oct. 31, 2018 | No Longer Used | |||
54868-2523-01 | 54868-2523 | Erythropoietin | Procrit | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 11, 1994 | In Use | ||
54868-5673-01 | 54868-5673 | Erythropoietin | Procrit | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | March 24, 2008 | In Use | ||
58468-1849-04 | 58468-1849 | Thyrotropin Alfa | Thyrogen | Hormonal Therapy | Thyroid Stimulating Hormone | Nov. 30, 1998 | May 30, 2019 | No Longer Used | |||
59385-0041-07 | 59385-0041 | Naldemedine, naldemedine tosylate | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 1, 2020 | In Use | ||
59385-0041-30 | 59385-0041 | Naldemedine, naldemedine tosylate | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | June 14, 2019 | In Use |
Found 10,000 results in 4 milliseconds — Export these results